What's Happening?
Recent research has highlighted the role of DNMT3B, a DNA methyltransferase, in promoting neuroblastoma cell growth and survival. Neuroblastoma, a common childhood tumor, often involves the silencing of tumor suppressor genes through promoter hypermethylation.
The study found that DNMT3B expression is higher in advanced neuroblastoma patients and correlates with poor prognosis. By knocking down DNMT3B, researchers observed increased expression of apoptosis-related genes and reduced tumor progression in both in vitro and in vivo models. The study also demonstrated that the DNMT3B inhibitor, nanaomycin A, has anti-tumor effects in a neuroblastoma xenograft model.
Why It's Important?
The findings are significant as they suggest a potential new therapeutic target for neuroblastoma, a cancer that currently has limited treatment options. Traditional DNA methyltransferase inhibitors have shown inadequate efficacy and high toxicity, making the selective targeting of DNMT3B a promising alternative. This approach could lead to more effective and less toxic treatments for patients, potentially improving survival rates and quality of life for children affected by this aggressive cancer.
